Meeting
2022 ASCO Annual Meeting
Pyrotinib plus nab-paclitaxel in patients with HER2-positive advanced or metastatic breast cancer: A multicenter, single-arm, open-label phase 2 trial.
Authors
Huan Li
Department of Breast internal medicine, Liaoning Cancer Hospital and Institute, Shenyang, China
Huan Li , Zhaohui Li , Min Yan , Xiujie Cui , Xuening Ji , Fenqi Fang , Yuyang Zhang , Xiaoxin Wang , Yan Wang , Xiangyu Guo , Mingxi Jing , Zhichao Gao , Hui Cao , Fangyuan Dong , Jie Wu , Cui Jiang , Yangyang Duan , Xiaorui Li , Yujun Jiang , Tao Sun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
ChiCTR1900023653
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1035)
DOI
10.1200/JCO.2022.40.16_suppl.1035
Abstract #
1035
Poster Bd #
413
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).
First Author: Ian E. Krop
Poster
2021 ASCO Annual Meeting
Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.
First Author: Sayeh Moazami Lavasani
Poster
2018 ASCO Annual Meeting
An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
First Author: Jiayu Wang
First Author: Nicholas Patrick McAndrew